SG10201912857XA - Mutated von willebrand factor - Google Patents

Mutated von willebrand factor

Info

Publication number
SG10201912857XA
SG10201912857XA SG10201912857XA SG10201912857XA SG10201912857XA SG 10201912857X A SG10201912857X A SG 10201912857XA SG 10201912857X A SG10201912857X A SG 10201912857XA SG 10201912857X A SG10201912857X A SG 10201912857XA SG 10201912857X A SG10201912857X A SG 10201912857XA
Authority
SG
Singapore
Prior art keywords
von willebrand
willebrand factor
mutated
mutated von
factor
Prior art date
Application number
SG10201912857XA
Inventor
Arna Andrews
Con Panousis
Kerstin Emmrich
Michael Wilson
Steve Dower
Matthew Hardy
Dallas Hartman
Original Assignee
CSL Behring Lengnau AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900033A external-priority patent/AU2016900033A0/en
Application filed by CSL Behring Lengnau AG filed Critical CSL Behring Lengnau AG
Publication of SG10201912857XA publication Critical patent/SG10201912857XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/718Starch or degraded starch, e.g. amylose, amylopectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79Transferrins, e.g. lactoferrins, ovotransferrins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201912857XA 2016-01-07 2017-01-06 Mutated von willebrand factor SG10201912857XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2016900033A AU2016900033A0 (en) 2016-01-07 Mutated von willebrand factor

Publications (1)

Publication Number Publication Date
SG10201912857XA true SG10201912857XA (en) 2020-02-27

Family

ID=59273072

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201805494WA SG11201805494WA (en) 2016-01-07 2017-01-06 Mutated von willebrand factor
SG10201912857XA SG10201912857XA (en) 2016-01-07 2017-01-06 Mutated von willebrand factor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201805494WA SG11201805494WA (en) 2016-01-07 2017-01-06 Mutated von willebrand factor

Country Status (14)

Country Link
US (1) US10808023B2 (en)
EP (1) EP3400238B1 (en)
JP (1) JP6755318B2 (en)
KR (1) KR20180098404A (en)
CN (1) CN108779165B (en)
AU (1) AU2017205776B2 (en)
BR (1) BR112018013822A2 (en)
CA (1) CA3008448A1 (en)
DK (1) DK3400238T3 (en)
ES (1) ES2881701T3 (en)
MX (1) MX2018008293A (en)
RU (1) RU2018128613A (en)
SG (2) SG11201805494WA (en)
WO (1) WO2017117630A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912498YA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated truncated von willebrand factor
DK3538133T3 (en) * 2016-11-11 2021-04-19 CSL Behring Lengnau AG TRUNKED VON WILLEBRAND FACTOR POLYPEPTIDES FOR THE TREATMENT OF HEMOPHILIA
US11141466B2 (en) 2017-06-22 2021-10-12 CSL Behring Lengnau AG Modulation of FVIII immunogenicity by truncated VWF
JP2021523878A (en) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド How to treat hemophilia A
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
FR2673632A1 (en) 1991-03-08 1992-09-11 Lille Transfusion Sanguine PROCESS FOR THE PREPARATION OF HUMAN VON WILLEBRAND FACTOR CONCENTRATE OF HIGH PURITY, SUITABLE FOR THERAPEUTIC USE
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
DE4435485C1 (en) 1994-10-04 1996-03-21 Immuno Ag Process for obtaining high-purity von Willebrand factor
JPH11501506A (en) 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター Chimeric cytokines and their use
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (en) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
EP0910628B1 (en) 1996-04-24 2006-03-08 The Regents of The University of Michigan Inactivation resistant factor viii
US6767707B2 (en) * 1996-07-19 2004-07-27 University Of Michigan DNA encoding canine von willebrand factor and methods of use
ATE283034T1 (en) 1998-04-27 2004-12-15 Opperbas Holding Bv PHARMACEUTICAL COMPOSITIONS CONTAINING FACTOR VIII AND NEUTRAL LIPOSOMES
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU2002248329B2 (en) 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
WO2002103024A2 (en) 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
WO2003093313A2 (en) 2002-04-29 2003-11-13 Baxter International Inc. Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
CN102139114A (en) 2003-02-26 2011-08-03 尼克塔治疗公司 Polymer factor VIII moiety conjugates
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP3552627A1 (en) 2003-05-06 2019-10-16 Bioverativ Therapeutics Inc. Clotting factor-fc chimeric proteins to treat hemophilia
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
BRPI0417916A (en) 2003-12-31 2007-04-10 Merck Patent Gmbh fc-erythropoietin fusion protein with improved pharmacokinetics
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
WO2006031524A2 (en) * 2004-09-10 2006-03-23 The Regents Of The Unversity Of Colorado Early detection of hemangiosarcoma and angiosarcoma
PL1824988T3 (en) 2004-11-12 2018-01-31 Bayer Healthcare Llc Site-directed modification of fviii
EP1835938B1 (en) 2004-12-27 2013-08-07 Baxter International Inc. Polymer-von willebrand factor-conjugates
AU2006233638A1 (en) 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation Factor VIII with enhanced stability and its derivates
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
CA2647314A1 (en) 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
WO2007144173A1 (en) 2006-06-14 2007-12-21 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
WO2008005290A2 (en) * 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
JP5448839B2 (en) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Modified clotting factor with long half-life in vivo
US20090136917A1 (en) * 2007-10-25 2009-05-28 Szalay Aladar A Systems and methods for viral therapy
US8173597B2 (en) * 2007-11-09 2012-05-08 Baxter International Inc. Modified recombinant factor VIII and von Willebrand factor and methods of use
CN103739712B (en) * 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 There is the Factor IX of the Half-life in vivo of prolongation, vWF or their complex
MX2012005527A (en) * 2009-11-13 2012-08-08 Grifols Therapeutics Inc Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto.
EP2814502B1 (en) * 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
US20130347134A1 (en) * 2012-06-21 2013-12-26 Thomas Diacovo Transgenic von willebrand factor animals and uses thereof
ES2844232T3 (en) 2014-07-02 2021-07-21 CSL Behring Lengnau AG Modified von Willebrand factor
US10663608B2 (en) * 2015-09-21 2020-05-26 Shanghai United Imaging Healthcare Co., Ltd. System and method for calibrating a PET scanner
SG10201912498YA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated truncated von willebrand factor

Also Published As

Publication number Publication date
EP3400238A1 (en) 2018-11-14
KR20180098404A (en) 2018-09-03
US20190016784A1 (en) 2019-01-17
AU2017205776A1 (en) 2018-07-05
JP2019504621A (en) 2019-02-21
RU2018128613A (en) 2020-02-07
US10808023B2 (en) 2020-10-20
SG11201805494WA (en) 2018-07-30
EP3400238A4 (en) 2019-07-10
AU2017205776B2 (en) 2020-09-10
CA3008448A1 (en) 2017-07-13
WO2017117630A1 (en) 2017-07-13
MX2018008293A (en) 2018-09-21
WO2017117630A9 (en) 2018-03-29
DK3400238T3 (en) 2021-07-26
JP6755318B2 (en) 2020-09-16
CN108779165B (en) 2022-12-02
BR112018013822A2 (en) 2018-12-11
ES2881701T3 (en) 2021-11-30
CN108779165A (en) 2018-11-09
EP3400238B1 (en) 2021-05-19

Similar Documents

Publication Publication Date Title
IL262482A (en) Novel polypeptides
HK1256525A1 (en) Mutated truncated von willebrand factor
SG11201702796WA (en) Mutated immunoglobulin-binding polypeptides
SG10201912857XA (en) Mutated von willebrand factor
GB201611530D0 (en) Novel polypeptides
GB201521640D0 (en) Novel porous materials
EP3164150A4 (en) Modified von willebrand factor
GB201803983D0 (en) Materials
GB201708113D0 (en) Materials
IL249294A0 (en) Preparation comprising factor viii and von willebrand factor peptides
HK1250724A1 (en) Methods for preparing modified von willebrand factor
HK1250625A1 (en) Truncated von willebrand factor polypeptides for treating hemophilia
GB201608197D0 (en) Novel proteins
IL253657A0 (en) Additive-incorporated building materials
GB201802484D0 (en) Tissue-adhesive materials
GB201619652D0 (en) Novel polypeptides
FI20155107A (en) The sample container
HK1244292A1 (en) Modified von willebrand factor having improved half-life
PL3225606T3 (en) Construction materials
GB201708013D0 (en) Materials
GB201614462D0 (en) Clotting factor
SG11201706657PA (en) Compounds for improving the half-life of von willebrand factor
AU2016900033A0 (en) Mutated von willebrand factor
AU2016900034A0 (en) Mutated truncated von willebrand factor
AU2014902532A0 (en) Modified von willebrand factor